Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Neuroendocrine Tumors 12Carcinoma, Neuroendocrine 8Carcinoma, Non-Small-Cell Lung 4Adrenocortical Carcinoma 4Thyroid Neoplasms 3Lung Neoplasms 3Carcinoid Tumor 3Vulvar Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Small Cell Lung Carcinoma 2Sarcoma 2Pheochromocytoma 2Penile Neoplasms 2Parathyroid Neoplasms 2Paraganglioma 2Ovarian Neoplasms 2Osteosarcoma 2Neurofibrosarcoma 2Mesothelioma 2Melanoma 2Hemangiosarcoma 2Gastro-enteropancreatic neuroendocrine tumor 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Carcinosarcoma 2Carcinoma, Renal Cell 2Carcinoma, Adenoid Cystic 2Adrenal Gland Neoplasms 2

Interventions

pembrolizumab 2Etoposide 2Cisplatin 2veliparib 1taxane 1liposomal doxorubicin 1Vinorelbine 1RRx-001 1Quality of Life 1Podophyllotoxin 1Platinum 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1PT-100 dipeptide 1Nivolumab 1Molecular Diagnostic Techniques 1Irinotecan 1Ipilimumab 1Immunotherapy 1Gemcitabine 1Drug Therapy 1Carboplatin 1Biological Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Nivolumab × Endocrine × Clear all
NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡